Title : Ira M. Jacobson MD: 8-week therapy for patients with HCV infection
link : Ira M. Jacobson MD: 8-week therapy for patients with HCV infection
Ira M. Jacobson MD: 8-week therapy for patients with HCV infection
Clinical Care Options
How New Data From AASLD 2017 Inform the Use of 8-Week Regimens for HCV
Ira M. Jacobson MD - 1/9/2018
Several studies presented at the 2017 AASLD meeting in Washington, DC, assessed 8-week therapy for patients with HCV infection. In this commentary, I discuss how key data from these studies may have an impact on management of patients with HCV infection.
Studies discussed:
Ira M. Jacobson MD - 1/9/2018
Several studies presented at the 2017 AASLD meeting in Washington, DC, assessed 8-week therapy for patients with HCV infection. In this commentary, I discuss how key data from these studies may have an impact on management of patients with HCV infection.
Studies discussed:
8-Week GZR/EBR for Treatment-Naive, Noncirrhotic Patients With Genotype 1b HCV Infection
GLE/PIB for Treatment-Naive Genotype 3 HCV
8-Week LDV/SOF for Acute Genotype 1 or 4 HCV and HIV Coinfection
GLE/PIB for Treatment-Naive Genotype 3 HCV
8-Week LDV/SOF for Acute Genotype 1 or 4 HCV and HIV Coinfection
Free registration required
http://ift.tt/2pOWjOp
http://ift.tt/2pOWjOp
New At Clinical Care Options
New Insights on NAFLD/NASH From AASLD 2017
Philip Newsome PhD, FRCPE - 1/8/2018
Here’s my take on how new data from AASLD 2017 on noninvasive imaging modalities and emerging investigational agents may affect the NAFLD/NASH patient management landscape.
How Injection Drug Use Affects HCV Treatment
Norah Terrault MD, MPH - 1/3/2018
Here’s my take on why colocalization of HCV treatment with other medical and social services may be ideal for persons who inject drugs.
New Insights on NAFLD/NASH From AASLD 2017
Philip Newsome PhD, FRCPE - 1/8/2018
Here’s my take on how new data from AASLD 2017 on noninvasive imaging modalities and emerging investigational agents may affect the NAFLD/NASH patient management landscape.
How Injection Drug Use Affects HCV Treatment
Norah Terrault MD, MPH - 1/3/2018
Here’s my take on why colocalization of HCV treatment with other medical and social services may be ideal for persons who inject drugs.
Thus Article Ira M. Jacobson MD: 8-week therapy for patients with HCV infection
That's an article Ira M. Jacobson MD: 8-week therapy for patients with HCV infection This time, hopefully can give benefits to all of you. well, see you in posting other articles.
You are now reading the article Ira M. Jacobson MD: 8-week therapy for patients with HCV infection with the link address https://theleknews.blogspot.com/2018/01/ira-m-jacobson-md-8-week-therapy-for.html
0 Response to "Ira M. Jacobson MD: 8-week therapy for patients with HCV infection"
Post a Comment